News Search Results
Feb 24, 2025, 17:31 ET HPV16-Positive Head and Neck Squamous Cell Carcinoma Market is Predicted to Exhibit Remarkable Growth at a CAGR of 9.2% by 2034 | DelveInsight
therapies, such as Bristol Myers Squibb, Merck, Merus, Exelixis, ISA Pharmaceuticals, Regeneron Pharmaceuticals, PDS Biotechnology, BioNTech, Cue Biopharma, Immutep, Iovance Biotherapeutics, Inovio Pharmaceuticals, MedImmune, Nykode Therapeutics, RAPT Therapeutics, and others
More news about: DelveInsight Business Research, LLP
Feb 24, 2025, 16:30 ET Crescent Biopharma Strengthens Leadership Team with Appointment of Three Key Executives
Feb. 24, 2025 /PRNewswire/ -- Crescent Biopharma, Inc. ("Crescent"), a private biotechnology company developing novel precision engineered molecules targeting validated biology to advance care for patients with solid tumors, today announced
More news about: Crescent Biopharma
Feb 24, 2025, 16:05 ET BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors
as the team advances new medicines for people with genetically defined conditions." About BioMarin BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The
More news about: BioMarin Pharmaceutical Inc.
Feb 24, 2025, 14:30 ET North Park Hires Advisor to Support and Retain First-Year STEM Students
North Park University offers a wide variety of STEM majors, including pre-medicine, pre-dentistry, biochemistry, and biotechnology. It remains committed to fostering a diverse, inclusive, and faith-centered environment where all students can succeed.
More news about: North Park University
Feb 24, 2025, 11:45 ET Rubin and Rudman Partner Julayne Lazar Named a 2025 "Go To Employment Lawyer" by Massachusetts Lawyers Weekly
Rubin and Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin and Rudman
Feb 24, 2025, 09:06 ET LabConnect and Australian Clinical Labs' Specialised Trials Announce Strategic Partnership in Australia and Asia Pacific Region
strengths to help get patients the medicines they need by meeting the growing regional demand of clinical trial support services for pharmaceutical, biotechnology, and clinical research organizations. ACL Specialised Trials is one of the leading clinical trials laboratories in Australia,
More news about: LabConnect
Feb 24, 2025, 09:06 ET LabConnect and Australian Clinical Labs' Specialised Trials Announce Strategic Partnership in Australia and Asia Pacific Region
strengths to help get patients the medicines they need by meeting the growing regional demand of clinical trial support services for pharmaceutical, biotechnology, and clinical research organizations. ACL Specialised Trials is one of the leading clinical trials laboratories in Australia,
More news about: LabConnect
Feb 24, 2025, 08:03 ET TFS HealthScience Announces Leadership Transition: Katarina Ageborg Appointed Chairman of the Board, Markus Granlund Named Acting CEO
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With nearly 700 professionals across 40 countries, TFS
More news about: TFS HealthScience
Feb 24, 2025, 08:00 ET Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T therapy for ovarian cancer, developed
More news about: Anixa Biosciences, Inc.
Feb 24, 2025, 08:00 ET Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm's Innovative T Cell Therapies for Solid Cancers
Feb. 24, 2025 /PRNewswire/ -- Swarm Oncology Ltd. ('Swarm Oncology' or 'Swarm'), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, today announced a strategic partnership
More news about: Cellex Cell Professionals
Feb 24, 2025, 08:00 ET Swarm Oncology Ltd. and Cellex Cell Professionals GmbH Announce Strategic Partnership to Advance Swarm's Innovative T Cell Therapies for Solid Cancers
Feb. 24, 2025 /PRNewswire/ -- Swarm Oncology Ltd. ('Swarm Oncology' or 'Swarm'), a biotechnology company pioneering novel T cell therapies to achieve long-term remission in patients with advanced solid cancers, today announced a strategic partnership
More news about: Cellex Cell Professionals
Feb 24, 2025, 07:55 ET TFS HealthScience Announces Leadership Transition: Katarina Ageborg Appointed Chairman of the Board, Markus Granlund Named Acting CEO
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With nearly 700 professionals across 40 countries, TFS
More news about: TFS HealthScience
Feb 24, 2025, 07:45 ET QurAlis to Participate in Upcoming Investor Conferences in March
QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic lateral
More news about: QurAlis
Feb 24, 2025, 07:00 ET Ultima Genomics increases output by over 50% and lowers sequencing costs by a further 20% with the introduction of UG 100 Solaris™
Proteomics Project to generate the largest and most comprehensive proteomics dataset in the world." "We believe the field of biotechnology is rapidly accelerating towards an era in which massive datasets and AI/ML techniques transform how drugs are discovered. The speed, quality, and
More news about: Ultima Genomics
Feb 24, 2025, 07:00 ET Biocon Biologics Launches Yesintek™ (ustekinumab-kfce) Biosimilar to Stelara® in the United States
international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India
More news about: Biocon Biologics Ltd.
Feb 24, 2025, 07:00 ET Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
prescription therapies or when those therapies are not advisable. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Feb 24, 2025, 07:00 ET Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
control and reduce longer-term complications.4 About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Feb 24, 2025, 05:45 ET ICON Public Limited Company Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Gross Law Firm
Feb 23, 2025, 16:00 ET ICLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
were insufficient to shield ICON from the adverse effects of a significant market downturn; (3) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Bronstein, Gewirtz & Grossman, LLC
Feb 23, 2025, 05:00 ET Review and Outlook of Sanyou Bio Intelligent Super-trillion Molecule Discovery Platform
treatment options to patients worldwide. About Sanyou Bio Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou has built the 4C business patterns that integrate "differentiated
More news about: Sanyou Bio
Feb 22, 2025, 04:52 ET Visionary Holdings: An Innovative Leader in Global Technology and Finance
integration," the company has established a diversified industrial ecosystem spanning artificial intelligence, digital finance, new energy, and biotechnology. Since being listed on NASDAQ (stock code: GV), its influence has continued to expand. 1. Technological Innovation: The Core Driver of
More news about: Visionary Holdings Inc.
Feb 21, 2025, 19:20 ET INVESTOR ALERT: ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ICLR
insufficient to shield ICON from the adverse effects of a significant market downturn; (iii) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Robbins Geller Rudman & Dowd LLP
Feb 21, 2025, 12:00 ET ICON plc (ICLR) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
offerings were insufficient to shield the Company from the adverse effects of a significant market downturn; (3) that the RFPs ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Feb 21, 2025, 05:45 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 11, 2025 in ICON Public Limited Company Lawsuit - ICLR
insufficient to shield the Company from the adverse effects of a significant market downturn; (c) the requests for proposals ICON received from its biotechnology customers during the Class Period were used in substantial part as price discovery tools, and thus were not indicative of underlying client demand;
More news about: Levi & Korsinsky, LLP
Feb 20, 2025, 17:31 ET Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight
Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma,
More news about: DelveInsight Business Research, LLP